Why the study?
Does empagliflozin improve health status in patients with heart failure and preserved ejection fraction?
Does empagliflozin improve health status in patients with heart failure and preserved ejection fraction?
Empagliflozin improves health status across major subgroups of patients with HFpEF, with a pronounced benefit in obese patients.
Answers are grounded in this paper and cite their sources.
May support empagliflozin for HFpEF health status, especially in obesity; hypothesis-generating and requires randomized confirmation.
Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater effect in obese patients.
No takes yet. Share an insight, caveat, or question.
Siddiqi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: